摘要
目的观察重组人红细胞生成素(rHuEpo)治疗恶性肿瘤贫血(MTA)的效果。方法治疗组患者接受rHuEpo皮下注射,10000U,隔日1次,疗程8周。疗效不明显或有缺铁实验室证据的患者加用琥珀酸亚铁0.1g口服,每日3次。治疗中如患者血红蛋白≤80g/L,可考虑给予输血。对照组不给予rHuEpo,其他同治疗组。结果治疗组有22例(73.3%)血红蛋白上升>20g/L,对照组仅4例(13.3%)血红蛋白上升>20g/L,两组有效率差异有统计学意义(P<0.01)。结论rHuEpo治疗MTA安全有效。
Objective To observe the effect of recombinant human erythropietin （rHuEpo） in treating malignant turnout anemia （MTA）. Methods Thirty cases of treated group were treated with rHuEpo 10 000 U, qod, lasted for 8 weeks . Thirty cases of control group were treated with support cares and the blood transfusion. Results The overall response rates of treated and control group were 73. 3%（22/ 30） and 13. 3% （4/30） respectively, and the increased Hb of treated group is more higher than that of control group （P〈0. 01） . Conclusion rHuEpo is effective and safe in treating MTA.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2005年第8期511-512,共2页
Cancer Research on Prevention and Treatment
关键词
恶性肿瘤贫血
红细胞生成素
恶性肿瘤
Malignant tumor anemia
Recombinant human erythropoietin
Malignant tumor
